

cambridge.org/hyg

P. J. White<sup>1,2</sup>  and J. Lewis<sup>1</sup> 

<sup>1</sup>MRC Centre for Global Infectious Disease Analysis and NIHR Health Protection Research Unit in Modelling Methodology, Imperial College London, London, UK and <sup>2</sup>Modelling and Economics Unit, National Infection Service, Public Health England, London, UK

## Letter to the Editor

**Cite this article:** White PJ, Lewis J (2019). Response to Kounali *et al.*'s letter of response. *Epidemiology and Infection* **147**, e273, 1. <https://doi.org/10.1017/S0950268819001584>

**Author for correspondence:**  
P. J. White, E-mail: [p.white@imperial.ac.uk](mailto:p.white@imperial.ac.uk)

Authors of the paper by Kounali *et al.* have repeatedly made the same challenge to the validity of our model-based method for estimating chlamydia prevalence from surveillance data, to which we have repeatedly responded, with evidence [1, 2] – none of which they have acknowledged.

Kounali *et al.*, a group which includes representation of England's National Chlamydia Screening Programme (NCSP), assert 'It is not possible... to make inferences about CT prevalence, or changes... over time, without information on [reason for testing]', yet despite the lack of such data NCSP states that 'modelling suggests that the level of testing that has been achieved in England... will probably have resulted in reductions in prevalence' [3]. Regarding Kounali *et al.*'s citations in support of their assertion, we have already responded to Soldan *et al.*'s letter [1, 2] and the commentary of Low and Smid [1], and we cited the paper by Miller in our original paper [4].

Estimating chlamydia incidence and prevalence from surveillance data is a subject of active debate, and methods have been described in several papers by ourselves and others [4–6]. We would direct readers to our original paper (and accompanying computer code) describing our model and its testing, validation, and sensitivity analysis considering unrecorded information, so they may evaluate our method for themselves [4].

The point on which we all agree is the importance of understanding testing behaviour and individuals' reasons for chlamydia testing. We hope that more-detailed surveillance data and population-based studies such as the fourth National Study of Sexual Attitudes and Lifestyles will provide the information required to better-understand patterns of chlamydia infection and optimise the effectiveness and cost-effectiveness of chlamydia control.

**Financial support.** PJW acknowledges joint Centre funding from the UK Medical Research Council and Department for International Development (grant number MR/R015600/1). PJW and JL acknowledge funding from the UK National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Modelling Methodology at Imperial College London, in partnership with Public Health England (grant number HPRU-2012-10080). The views expressed are those of the authors and not necessarily those of the Department of Health, Department for International Development, MRC, NHS, NIHR, or Public Health England.

**Conflict of interest.** None.

## References

1. White PJ and Lewis J (2018) Authors' reply. *Lancet Public Health* **3**, e417.
2. White PJ and Lewis J (2019) Letter to editor in response to Has *Chlamydia trachomatis* prevalence in young women in England, Scotland and Wales changed? Evidence from national probability surveys. *Epidemiology and Infection* **147**, e271. Cambridge University Press.
3. Available at <https://www.gov.uk/government/publications/ncsp-programme-overview/ncsp-programme-overview> (Accessed 4 September 2019).
4. Lewis J and White PJ (2017) Estimating local chlamydia incidence and prevalence using surveillance data. *Epidemiology* **28**, 492–502.
5. Ali H *et al.* (2015) A new approach to estimating trends in chlamydia incidence. *Sexually Transmitted Infections* **91**, 513–519.
6. Lewis J and White PJ (2018) Changes in chlamydia prevalence and duration of infection estimated from testing and diagnosis rates in England: a model-based analysis using surveillance data, 2000–15. *The Lancet Public Health* **3**, e271–e278.

© The Author(s) 2019. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.